ICON Public (NASDAQ:ICLR) Releases Earnings Results

ICON Public (NASDAQ:ICLR) issued its quarterly earnings data on Wednesday. The medical research company reported $3.42 EPS for the quarter, topping analysts’ consensus estimates of $3.41 by $0.01, Zacks reports. ICON Public had a return on equity of 11.91% and a net margin of 9.00%.

ICON Public Stock Up 1.4 %

ICON Public stock traded up $2.67 during midday trading on Wednesday, hitting $191.32. The stock had a trading volume of 1,456,565 shares, compared to its average volume of 951,855. The company has a current ratio of 1.34, a quick ratio of 1.34 and a debt-to-equity ratio of 0.35. The stock has a market cap of $15.78 billion, a P/E ratio of 21.33, a P/E/G ratio of 1.70 and a beta of 1.19. ICON Public has a 12 month low of $181.51 and a 12 month high of $347.72. The business has a fifty day moving average price of $203.63 and a 200 day moving average price of $246.83.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. Robert W. Baird reduced their price objective on ICON Public from $249.00 to $225.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 20th. Baird R W cut ICON Public from a “strong-buy” rating to a “hold” rating in a research note on Thursday, October 24th. The Goldman Sachs Group dropped their target price on ICON Public from $370.00 to $280.00 and set a “buy” rating on the stock in a research report on Friday, October 25th. JPMorgan Chase & Co. dropped their target price on ICON Public from $280.00 to $265.00 and set an “overweight” rating on the stock in a research report on Monday, February 3rd. Finally, Citigroup dropped their target price on ICON Public from $300.00 to $290.00 and set a “buy” rating on the stock in a research report on Monday, January 6th. Four investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $283.92.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.